Patients With COVID-19 May Initially Present With Extrapulmonary Symptoms Such as Diarrhea
Gastrointestinal symptoms were reported to be the chief complaint in nearly half of patients diagnosed with coronavirus disease 2019.
Gastrointestinal symptoms were reported to be the chief complaint in nearly half of patients diagnosed with coronavirus disease 2019.
Patients with cardiovascular disease diagnosed with COVID-19 are urged to continue taking their angiotensin-converting enzyme inhibitor and angiotensin receptor blocker medications as prescribed.
The first US clinical trial to assess the efficacy and safety of an investigational broad-spectrum antiviral agent, remdesivir (Gilead Sciences, Inc.), for the treatment of coronavirus disease 2019.
Although no differences were seen in the standardized mean differences for respiratory rate or oxygen saturation when comparing nebulized normal saline with another placebo, a difference in respiratory scores which favored nebulized normal saline by -0.9 points was observed 60 minutes posttreatment.
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
The most important factors in deciding whether or not to stock adult vaccines were found to be economic in nature.
Evidence for the effectiveness of intranasal corticosteroids in the management of non-allergic rhinitis appears to be lacking.
For patients with chronic obstructive pulmonary disease (COPD), inhaled corticosteroid (ICS) use was associated with an increased risk of pneumonia, according to the results of a recently published meta-analysis.